Single-cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2008 Oct 7

PMID 18835035

Citations 120

Authors

Nikesh Kotecha

Nikki J Flores

Jonathan M Irish

Erin F Simonds

Debbie S Sakai

Sophie Archambeault

Ernesto Diaz-Flores

Marc Coram

Kevin M Shannon

Garry P Nolan

Mignon L Loh

Affiliations

Soon will be listed here.

Abstract

Progress in understanding the molecular pathogenesis of human myeloproliferative disorders (MPDs) has led to guidelines incorporating genetic assays with histopathology during diagnosis. Advances in flow cytometry have made it possible to simultaneously measure cell type and signaling abnormalities arising as a consequence of genetic pathologies. Using flow cytometry, we observed a specific evoked STAT5 signaling signature in a subset of samples from patients suspected of having juvenile myelomonocytic leukemia (JMML), an aggressive MPD with a challenging clinical presentation during active disease. This signature was a specific feature involving JAK-STAT signaling, suggesting a critical role of this pathway in the biological mechanism of this disorder and indicating potential targets for future therapies.

Citing Articles

Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan Derivatives.

Schoepf A, Gebhart M, Federspiel M, Heidegger I, Puhr M, Hotze M J Med Chem. 2024; 68(1):287-306.

PMID: 39693499 PMC: 11726677. DOI: 10.1021/acs.jmedchem.4c01865.

Single Cell Profiling Distinguishes Leukemia-Selective Chemotypes.

Thirman H, Hayes M, Brown L, Porco Jr J, Irish J bioRxiv. 2024; .

PMID: 38826485 PMC: 11142275. DOI: 10.1101/2024.05.01.591362.

A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemia.

Edtmayer S, Witalisz-Siepracka A, Zdarsky B, Heindl K, Weiss S, Eder T Cell Death Dis. 2024; 15(5):369.

PMID: 38806478 PMC: 11133483. DOI: 10.1038/s41419-024-06749-9.

Distinct roles of hematopoietic cytokines in the regulation of leukemia stem cells in murine MLL-AF9 leukemia.

Li Y, Seet C, Mack R, Joshi K, Runde A, Hagen P Stem Cell Reports. 2023; 19(1):100-111.

PMID: 38101400 PMC: 10828676. DOI: 10.1016/j.stemcr.2023.11.003.

Germline bi-allelic alteration predisposes to a neonatal juvenile myelomonocytic leukemia-like disorder.

Arfeuille C, Vial Y, Cadenet M, Caye-Eude A, Fenneteau O, Neven Q Haematologica. 2023; 109(8):2542-2554.

PMID: 37981895 PMC: 11290538. DOI: 10.3324/haematol.2023.283917.

References

Meshinchi S, Stirewalt D, Alonzo T, Zhang Q, Sweetser D, Woods W . Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 2003; 102(4):1474-9. DOI: 10.1182/blood-2003-01-0137. View

Yu W, Hawley T, Hawley R, Qu C . Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene. 2003; 22(38):5995-6004. DOI: 10.1038/sj.onc.1206846. View

Zwaan C, Meshinchi S, Radich J, Veerman A, Huismans D, Munske L . FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood. 2003; 102(7):2387-94. DOI: 10.1182/blood-2002-12-3627. View

Shuai K, Liu B . Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003; 3(11):900-11. DOI: 10.1038/nri1226. View

Braun B, Tuveson D, Kong N, Le D, Kogan S, Rozmus J . Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 2003; 101(2):597-602. PMC: 327193. DOI: 10.1073/pnas.0307203101. View

Chan I, Kutok J, Williams I, Cohen S, Kelly L, Shigematsu H . Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004; 113(4):528-38. PMC: 338267. DOI: 10.1172/JCI20476. View

Loh M, Vattikuti S, Schubbert S, Reynolds M, Carlson E, Lieuw K . Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2003; 103(6):2325-31. DOI: 10.1182/blood-2003-09-3287. View

Van Etten R . Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res. 2004; 28 Suppl 1:S21-8. DOI: 10.1016/j.leukres.2003.10.005. View

Emanuel P . Juvenile myelomonocytic leukemia. Curr Hematol Rep. 2004; 3(3):203-9. View

10.

Le D, Kong N, Zhu Y, Lauchle J, Aiyigari A, Braun B . Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004; 103(11):4243-50. DOI: 10.1182/blood-2003-08-2650. View

11.

Kunz M, Ibrahim S . Molecular responses to hypoxia in tumor cells. Mol Cancer. 2003; 2:23. PMC: 155638. DOI: 10.1186/1476-4598-2-23. View

12.

Irish J, Hovland R, Krutzik P, Perez O, Bruserud O, Gjertsen B . Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 2004; 118(2):217-28. DOI: 10.1016/j.cell.2004.06.028. View

13.

Araki T, Mohi M, Ismat F, Bronson R, Williams I, Kutok J . Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med. 2004; 10(8):849-57. DOI: 10.1038/nm1084. View

14.

Emanuel P, Bates L, Castleberry R, Gualtieri R, Zuckerman K . Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991; 77(5):925-9. View

15.

Kalra R, Paderanga D, Olson K, Shannon K . Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood. 1994; 84(10):3435-9. View

16.

Ilaria Jr R, Van Etten R . P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996; 271(49):31704-10. DOI: 10.1074/jbc.271.49.31704. View

17.

Niemeyer C, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U . Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997; 89(10):3534-43. View

18.

Cambier N, Baruchel A, Schlageter M, Menot M, Wattel E, Fenaux P . Chronic myelomonocytic leukemia: from biology to therapy. Hematol Cell Ther. 1997; 39(2):41-8. DOI: 10.1007/s00282-997-0041-4. View

19.

Bader-Meunier B, Tchernia G, Mielot F, Fontaine J, Thomas C, Lyonnet S . Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr. 1997; 130(6):885-9. DOI: 10.1016/s0022-3476(97)70273-7. View

20.

Arico M, Biondi A, Pui C . Juvenile myelomonocytic leukemia. Blood. 1997; 90(2):479-88. View